Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized comparator-controlled trial of pembrolizumab versus BCG in high-risk non-muscle invasive bladder cancer
2018-001967-22Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab in bladder cancer and bladder neoplasm (2 arms), sponsored by Merck & Co. Primary endpoint: Cohort A primary endpoint. Started Sep 2018; status: active.
02
Drugs
03
Conditions
bladder cancerbladder neoplasm
Beyond the preview
Go deeper on 2018-001967-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001967-22.